These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 30498263

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease.
    Boboridis KG, Konstas AGP.
    Expert Opin Pharmacother; 2018 Jun; 19(9):1027-1039. PubMed ID: 29847195
    [Abstract] [Full Text] [Related]

  • 6. Topical ciclosporin in the treatment of ocular surface disorders.
    Tatlipinar S, Akpek EK.
    Br J Ophthalmol; 2005 Oct; 89(10):1363-7. PubMed ID: 16170133
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
    Med Lett Drugs Ther; 2019 Jul 29; 61(1577):116-118. PubMed ID: 31381551
    [No Abstract] [Full Text] [Related]

  • 8. When eyes get dry and what you can try. If artificial tears didn't work, anti-inflammatory cyclosporine drops may.
    Harv Health Lett; 2010 Oct 29; 35(12):4-6. PubMed ID: 21089264
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ophthalmic cyclosporine use in ocular GVHD.
    Lelli GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI.
    Cornea; 2006 Jul 29; 25(6):635-8. PubMed ID: 17077652
    [Abstract] [Full Text] [Related]

  • 16. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD, Pflugfelder SC, Tauber J, Foulks GN.
    Ophthalmology; 2005 Oct 29; 112(10):1790-4. PubMed ID: 16102833
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes.
    Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK.
    Arch Ophthalmol; 2000 Nov 29; 118(11):1489-96. PubMed ID: 11074805
    [Abstract] [Full Text] [Related]

  • 19. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K, Stevenson OD, Mundorf TK, Reis BL.
    Ophthalmology; 2000 Apr 29; 107(4):631-9. PubMed ID: 10768324
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.